Companies believe AI isn't delivering because technology moves too fast, so they invest in training and agile frameworks. The real, invisible problems are structural: ambiguous decision rights, siloed data ownership, and misaligned employee incentives. Solving for 'speed' when the foundation is broken guarantees failure.

Failing to conduct comprehensive screening for strain selection and media development at the project's start creates issues that become significantly more difficult and expensive to resolve later. Small, early-stage problems can derail downstream processing and scale-up efforts entirely.

While automation is typically associated with increasing speed, its most crucial function in complex 3D cell culture is mitigating human error and process variability. For drug discovery, where inconsistent results are a major struggle, automation provides the data consistency needed for reliable outcomes, a more valuable benefit than throughput alone.

The misconception that automation equals simplicity causes teams to underestimate the need for experts in assay development, biology, and data analysis. This leads to poorly designed experiments and unreliable data when teams believe complex systems require just 'pushing a button.'

The most common failure in automation is focusing on the robot or software. True success is determined by deeply understanding and codifying the entire process, including its environment and inherent variabilities. Getting the requirements right is the core challenge; the technology itself is secondary.

Before implementing AI automation, you must validate and refine a process manually. Applying AI to a flawed system doesn't fix it; it just makes the system fail more efficiently and at a larger scale, wasting significant time and resources.

The manufacturing process fundamentally alters a cell therapy's properties. This creates a conundrum: starting with expensive, fully-automated systems is often unfeasible for early trials, but switching to automation later is risky. The high burden of proving the new process yields an equivalent product can stall late-stage development.

For live cell therapies, the manufacturing process fundamentally shapes the biological product. Teams often rush to scale production, focusing on yield and cost. Instead, they should first fully understand how the process impacts cell potency and function to avoid effectively scaling the wrong biology.

A common error is screening strains or media in a simple batch mode when the final process will be fed-batch. This mismatch leads to incorrect candidate ranking and selection, forcing teams to restart the development process once the error becomes apparent during scale-up.